Phyllis Gotlib Sells 4,782 Shares of American Well Co. (NYSE:AMWL) Stock

American Well Co. (NYSE:AMWL - Get Free Report) insider Phyllis Gotlib sold 4,782 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $6.61, for a total transaction of $31,609.02. Following the completion of the transaction, the insider now directly owns 141,849 shares of the company's stock, valued at $937,621.89. This trade represents a 3.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

American Well Price Performance

Shares of NYSE:AMWL remained flat at $6.92 on Friday. 8,796 shares of the company's stock were exchanged, compared to its average volume of 86,532. American Well Co. has a 1 year low of $5.00 and a 1 year high of $12.95. The company's fifty day moving average price is $7.11 and its two-hundred day moving average price is $8.47. The firm has a market cap of $108.02 million, a P/E ratio of -0.49 and a beta of 1.19.

American Well (NYSE:AMWL - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($1.73) EPS for the quarter, beating the consensus estimate of ($3.09) by $1.36. The firm had revenue of $66.83 million for the quarter, compared to analyst estimates of $60.15 million. American Well had a negative net margin of 81.83% and a negative return on equity of 56.73%. Equities analysts predict that American Well Co. will post -9.34 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AMWL. Stifel Nicolaus reduced their target price on shares of American Well from $10.00 to $8.00 and set a "hold" rating on the stock in a research report on Friday, May 2nd. Needham & Company LLC reiterated a "hold" rating on shares of American Well in a research report on Friday, May 2nd. UBS Group lowered their target price on American Well from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Truist Financial decreased their price target on American Well from $12.00 to $7.50 and set a "hold" rating on the stock in a report on Thursday, April 10th. Finally, Piper Sandler reissued a "neutral" rating and set a $8.00 price objective (down from $10.00) on shares of American Well in a report on Friday, May 23rd. Six equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, American Well currently has a consensus rating of "Hold" and a consensus target price of $9.67.

Institutional Investors Weigh In On American Well

Hedge funds have recently made changes to their positions in the stock. Compagnie Lombard Odier SCmA acquired a new position in American Well during the 4th quarter worth approximately $45,000. Sapient Capital LLC acquired a new position in shares of American Well during the first quarter worth $79,000. OMERS ADMINISTRATION Corp acquired a new position in shares of American Well during the fourth quarter worth $76,000. Chancellor Financial Group WB LP bought a new position in shares of American Well in the 4th quarter valued at $83,000. Finally, Corton Capital Inc. acquired a new stake in shares of American Well during the 4th quarter valued at $134,000. 56.05% of the stock is currently owned by institutional investors and hedge funds.

About American Well

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.